Pediatric Blood & Cancer, a leading journal dedicated to research on blood disorders and malignant diseases in children, adolescents, and young adults, has released its latest performance metrics.

The journal recorded a CiteScore of 3.9 and a Journal Impact Factor of 2.4, reflecting its continued standing as a key publication venue for basic and clinical research in pediatric hematology and oncology. The journal covers a broad scope, including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics, as well as emerging treatment approaches such as hematopoietic stem cell transplantation, immunology, and gene therapy.

Notably, the journal reported a 34% acceptance rate and a median submission-to-first-decision time of just five days, underscoring a relatively swift and selective peer review process compared to many journals in the field.

These metrics offer authors and researchers in pediatric oncology and hematology useful benchmarks when considering where to submit their work.

Read more about the journal’s impact and reach here